Molecular biologist Suzanne Stratton worked to improve clinical trials Carle Cancer Center in Urbana, Illinois, when she was fired late last year prompting an investigation into the center of the standards, according to a report in on New York Times .
Stratton argues that his removal raises questions about the quality and safety studies in this and other community health centers funded by the National Cancer Institute.
Stratton told Times she was hired several years ago to help oversee the expansion of the program in Carle center clinical study, partly funded by the NCI in a new push to bring innovative medicines to a broader community. After a disagreement with the bosses, Stratton was dismissed in 08; She then informed NCI on the problems she saw, including an allegation that doctors exaggerating the benefits of testing and do not get proper consent from patients.
NCI investigation, but agency officials were not immediately available to discuss results. The spokesman Carle Centre did not respond to telephone and electronic messages of Science Insider requesting comment. [see update below]
In a statement released today, Carle Clinic Stratton challenged the allegations, but refused to discuss them because they involve "a personal problem." The statement continues: "Many of the concerns raised in the [ New York Times ] were deemed unfounded or adequately addressed by an audit of the US Department of Health and Office services social Human Research Protections (. OHRP) for other issues, we have worked diligently to respond "
the full text of the statement :.
Carle Clinic is aware of an article in the October 23 issue of New York Times regarding the research program in Carle Cancer Center.
Stratton Suzanne is a former employee of Carle Hospital Foundation who provided information about the history. We do not agree with most of the statements attributed to it but can not discuss her allegations further, as this is a matter of Carle Foundation hospital staff.
Many of the concerns raised in the article were deemed unfounded or adequately addressed by an audit of the US Department of the Office of Health and Human Services for Human Research Protections (OHRP). For other questions, we have worked diligently to address them.
It is important to note that many of OHRP's concerns are administrative issues such as the lack of clear policies and procedures. The OHRP determination letter did not indicate in any way that patients have suffered harm due to participation in clinical trials. Furthermore, the determination of OHRP has not indicated that the integrity of any investigation has been compromised by the problems identified, and in particular, found no failures to obtain informed consent as it was alleged by Mrs. Stratton.
Significantly OHRP has taken note of our commitment to patient safety as shown in its last letter in Carle Clinic "during the evaluation OHRP on site, members of the IRB, the IRB staff, and investigators displayed an enthusiastic and sincere concern the protection of human subjects. "
The National Cancer Institute and National Institutes of Health challenged Article of the New York Times and has requested the publication to publish a correction. This formal request in writing can be read here.
We will continue to meet additional demands OHRP may cause and appreciate the consideration and the opportunity to improve research at Carle Clinic. Carle Clinic has been active in clinical research for over 25 years, during which the lives of many patients improved by advances directly or indirectly, made as a result of this research. Research is an important part of advancing cancer care, and we remain committed to clinical research and high-quality patient care.
Jennifer Hendricks Kaufmann
Manager, Public Relations and Communications
Carle Clinic
0 Komentar